EMG
SUPN icon

Ellington Management Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Ellington Management Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,814
Closed -$509K – 841
2017
Q2 		$509K Buy
+11,814
New +$420K 0.07% 230
2015
Q2 		– Sell
-44,500
Closed -$538K – 870
2015
Q1 		$538K Sell
44,500
-16,900
-28% -$160K 0.11% 257
2014
Q4 		$510K Buy
61,400
+46,200
+304% +$388K 0.17% 196
2014
Q3 		$132K Buy
+15,200
New +$137K 0.09% 253

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Ellington Management Group's SUPN Position: Q3 2017 in Review

Ellington Management Group sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 11,814 shares — an estimated $509K sold.

Ellington Management Group first reported a position in SUPN in Q3 2014 and held it in 4 quarters. The position peaked at $538K in Q1 2015. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

  • Ellington Management Group reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Ellington Management Group sold 11,814 Supernus Pharmaceuticals shares in Q3 2017, an estimated $509K.
  • Ellington Management Group first reported a position in Supernus Pharmaceuticals in Q3 2014 and held it in 4 quarters.
  • Ellington Management Group's Supernus Pharmaceuticals position peaked at $538K in Q1 2015.
  • 275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Ellington Management Group's 13F filing for Q3 2017, filed 14 Nov 2017.